The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review.
This review examines the use of exenatide twice daily in managing changes in markers of cardiovascular risk in patients with type 2 diabetes.



Type 2 diabetes is a progressive metabolic disorder, which results from defects in insulin secretion and/or insulin action leading to chronic hyperglycaemia and associated cardiovascular complications. Despite the use of diet, exercise, oral antihyperglycaemic agents and insulin, the progressive nature of the condition means that the levels of the preventive and treatment measures would have to be increased and/or new therapies have to be developed in order to address the long term impact of type 2 diabetes. The advent of exenatide, a glucagon-like peptide-1 receptor agonist provides a useful basis for managing type 2 diabetes and related cardiovascular complications without the side effects of regular diabetes therapies. However, exenatide twice daily is often used in combination with other therapies, although the mechanism of exenatide in managing diabetes and and associated cardiovascular risks and complications remain complex and still evolving.



A range of databases including EBSCOhost online research database were used to access articles based on PICO (Population, Interventions, Comparative Interventions, Outcomes) framework and Boolean operators.



Eleven randomised controlled studies which met the inclusion criteria were selected for this review. Nine of the eleven studies showed significant decrease in body weight among participants in the exenatide group compared with placebo or control group while the other two studies did not report statistically significant differences in body weight. In adition, all the studies showed statistically significant decrease in glycated haemoglobin (HbA1c) in the exenatide group compared to controls except in one study. In the present review, the seven studies, which looked at the effect of exenatide twice daily on lipid profile, did not find any significant difference between the exenatide group and the control group except for High density lipoprotein-cholesterol in two of the studies. However, statistically significant decrease was observed between exenatide group and controls with respect to blood pressure (systolic and/or diastolic) in these studies.



It would appear that exenatide is more effective in reducing body weight in patients with type 2 diabetes when used in combination with metformin than when used alone or in combination with thiazolidinedione. The findings of this review would suggest that exenatide twice daily may be useful in managing cardiovascular risks and complications by reducing body weight, HbA1c and blood pressure.
Faculty of Education and Health, University of Greenwich, Avery Hill Campus, London SE9 2UG, UK. o.ojo@greenwich.ac.uk.
Omorogieva
O
Ojo
D015415:Biomarkers / Q000378:metabolism*; D001835:Body Weight / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood; D000077270:Exenatide; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis / Q000187:drug effects; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D007328:Insulin; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000008:administration & dosage* / Q000494:pharmacology; D012307:Risk Factors; D045162:Thiazolidinediones; D014688:Venoms / Q000008:administration & dosage* / Q000494:pharmacology
D015415:Biomarkers; D000077270:Exenatide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D010455:Peptides; D045162:Thiazolidinediones; D014688:Venoms; C089946:2,4-thiazolidinedione
cardiovascular risk; exenatide; glycaemic control; glycated haemoglobin; metformin; type 2 diabetes
Cardiovasc Diabetol. 2010 Jan 28;9:6
20109208
Ann Intern Med. 2011 Jan 18;154(2):103-12
21138825
Diabetes Care. 2005 May;28(5):1092-100
15855572
Cardiovasc Diabetol. 2015 Sep 04;14:116
26338040
PLoS One. 2015 Apr 13;10(4):e0123116
25874454
Diabetes Care. 2012 May;35(5):955-8
22432107
Can J Physiol Pharmacol. 2013 Sep;91(9):724-32
23984793
Diabetes Care. 2011 May;34 Suppl 2:S279-84
21525469
Clin Endocrinol (Oxf). 2014 Apr;80(4):545-53
23574529
Diabet Med. 2014 Sep;31(9):1055-63
24894815
Int J Obes (Lond). 2014 Sep;38(9):1165-71
24406481
Am J Med. 2010 May;123(5):468.e9-17
20399326
Cardiovasc Diabetol. 2012 Oct 12;11:127
23062182
Cardiovasc Diabetol. 2011 Mar 16;10:22
21410975
J Intern Med. 2013 Jan;273(1):94-101
23009556
Drugs. 2014 Mar;74(3):325-51
24435322
Diabetes Obes Metab. 2006 Jul;8(4):419-28
16776749
Lancet. 2012 Jun 16;379(9833):2270-8
22683137
Diabetes Care. 2011 Mar;34(3):604-6
21285388
Diabetes Care. 2009 Jan;32(1):193-203
18945920
Diabetes Obes Metab. 2010 Dec;12(12):1058-65
20977576
J Diabetes Investig. 2011 Jun 5;2(3):210-7
24843486
Drugs R D. 2007;8(3):145-53
17472410
Diabet Med. 2008 Nov;25(11):1295-301
19046219
Diabetes Obes Metab. 2011 Apr;13(4):302-12
21205117
Diabetes Obes Metab. 2006 Jul;8(4):436-47
16776751
Diabetes Care. 2005 May;28(5):1083-91
15855571
Clin Orthop Relat Res. 2007 Feb;455:23-9
17279036
Cardiovasc Diabetol. 2016 Feb 24;15:38
26912057
Cardiovasc Diabetol. 2014 Oct 22;13:142
25338737